Possible microangiopathic overlap between COVID-19 and Shiga toxin-associated hemolytic uremic syndrome
Corresponding Author
Karolis Azukaitis
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Correspondence
Karolis Azukaitis, Santariskiu g. 4, Vilnius, LT-08406, Lithuania.
Email: [email protected]
Search for more papers by this authorAusteja Stankute-Kolosova
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorVilmanta Burokiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorSonata Saulyte Trakymiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorAugustina Jankauskiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorCorresponding Author
Karolis Azukaitis
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Correspondence
Karolis Azukaitis, Santariskiu g. 4, Vilnius, LT-08406, Lithuania.
Email: [email protected]
Search for more papers by this authorAusteja Stankute-Kolosova
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorVilmanta Burokiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorSonata Saulyte Trakymiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorAugustina Jankauskiene
Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Search for more papers by this authorCONFLICT OF INTEREST
The authors declare that there is no conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| pbc29798-sup-0002-tableS1.docx14.7 KB | Supporting Table S1 Summary of main laboratory test results at the time of admission |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins (Basel). 2020; 12(2): E67. https://doi.org/10.3390/toxins12020067
- 2Trachtman H, Austin C, Lewinski M, Stahl RAK. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012; 8(11): 658-669. https://doi.org/10.1038/nrneph.2012.196
- 3Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021; 47:100761. https://doi.org/10.1016/j.blre.2020.100761
- 4Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023-1026. https://doi.org/10.1111/jth.14810
- 5Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020; 158(3): 1143-1163. https://doi.org/10.1016/j.chest.2020.05.559
- 6Mir TH. Thrombotic microangiopathy (aHUS/iTTP) reported so far in COVID-19 patients: the virus alone or an omnium gatherum of mechanisms and etiologies? Crit Rev Oncol Hematol. 2021; 162:103347. https://doi.org/10.1016/j.critrevonc.2021.103347
- 7Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020; 4(23): 6051-6063. https://doi.org/10.1182/bloodadvances.2020003471
- 8Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021; 19(2): 513-521. https://doi.org/10.1111/jth.15191
- 9Simpson HD, Johnson E, Britton J, Braksick S. Alternating hemiparesis in the context of hemolytic uremic syndrome and COVID-19 positivity. Epilepsy Behav Rep. 2021; 16:100468. https://doi.org/10.1016/j.ebr.2021.100468
- 10Wada H, Matsumoto T, Su. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thrombosis J. 2018; 16: 14. https://doi.org/10.1186/s12959-018-0168-2
- 11Buelli S, Zoja C, Remuzzi G, Morigi M. Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome. Microorganisms. 2019; 7(1): E15. https://doi.org/10.3390/microorganisms7010015
- 12Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020; 18(11): 3099-3105. https://doi.org/10.1111/jth.15073
